1. Eunice Kennedy Shiver National Institute of Child Health and Human Developoment. Intellectual and developmental disabilities (IDDs): condition information. National Institutes of Health. https://www.nichd.nih.gov/health/topics/idds/conditioninfo/default
. Published 2016. Accessed July 9, 2020.
2. Kripke C. Adults with developmental disabilities: a comprehensive approach to medical care. Am Fam Physician 2018;97:649–656.
3. Coppus AMW. People with intellectual disability: what do we know about adulthood and life expectancy? Dev Disabil Res Rev 2013;18:6–16.
4. Henderson RC, Kairalla JA, Barrington JW, et al. Longitudinal changes in bone density in children and adolescents with moderate to severe cerebral palsy. J Pediatr 2005;146:769–775.
5. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 2006;194(2 suppl):S3–S11.
6. Jasien J, Daimon CM, Maudsley S, et al. Aging and bone health in individuals with developmental disabilities. Int J Endocrinol 2012;2012:469235.
7. Mirza F, Canalis E. Management of endocrine disease: secondary osteoporosis: pathophysiology and management. Eur J Endocrinol 2015;173:R131–R151.
8. Beerhorst K, Huvers F, Renier W. Severe early onset osteopenia and osteoporosis caused by antiepileptic drugs. Neth J Med 2005;63:222–226.
9. Kyvernitakis I, Kostev K, Nassour T, et al. The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. Osteoporos Int 2017;28:291–297.
10. Paksu MS, Vurucu S, Karaoglu A, et al. Osteopenia in children with cerebral palsy can be treated with oral alendronate. Childs Nervous System 2012;28:283–286.
11. Tang JYM, Luo H, Wong GHY, et al. Bone mineral density from early to middle adulthood in persons with Down syndrome. J Intellect Disabil Res 2019;63:936–946.
12. García-Hoyos M, Riancho JA, Valero C. Salud ósea en el síndrome de Down. Med Clín 2017;149:78–82.
13. Snow ME, Keiver K. Prenatal ethanol exposure disrupts the histological stages of fetal bone development. Bone 2007;41:181–187.
14. Beyond Seizures: Comorbid Clinical Features and Multidisciplinary Management of Lennox-Gastaut Syndrome and Dravet Syndrome. Carlsbad, CA: Greenwich Biosciences; 2018.
15. Marreiros H. Update on bone fragility in spina bifida. J Pediatr Rehabil Med 2018;11:265–281.
16. Zylstra RG, Porter LL, Shapiro JL, et al. Prevalence of osteoporosis in community-dwelling individuals with intellectual and/or developmental disabilities. J Am Med Dir Assoc 2008;9:109–113.
17. Lohiya GS, Crinella FM, Tan-Figueroa L, et al. Fracture epidemiology and control in a developmental center. West J Med 1999;170:203–209.
18. Glick NR, Fischer MH, Heisey DM, et al. Epidemiology of fractures in people with severe and profound developmental disabilities. Osteoporos Int 2005;16:389–396.
19. Jeremiah MP, Unwin BK, Greenawald MH, et al. Diagnosis and management of osteoporosis. Am Fam Physician 2015;92:261–268.
20. Sheridan KJ. Osteoporosis in adults with cerebral palsy. Dev Med Child Neurol 2009;51(suppl 4):38–51.
21. Harcke HT, Taylor A, Bachrach S, et al. Lateral femoral scan: an alternative method for assessing bone mineral density in children with cerebral palsy. Pediatr Radiol 1998;28:241–246.
22. Link TM. Osteoporosis imaging: state of the art and advanced imaging. Radiology 2012;263:3–17.
23. Stagi S, Cavalli L, Cavalli T, et al. Peripheral quantitative computed tomography (pQCT) for the assessment of bone strength in most of bone affecting conditions in developmental age: a review. Ital J Pediatr 2016;42:88–88.
24. Lewiecki EM, Silverman SL. Redefining osteoporosis treatment: who to treat and how long to treat. Arq Bras Endocrinol Metabol 2006;50:694–704.
25. Carroll DD, Courtney-Long EA, Stevens AC, et al. Vital signs: disability and physical activity—United States, 2009-2012. MMWR Morb Mortal Wkly Rep 2014;63:407–413.
26. Nair R, Maseeh A. Vitamin D: the "sunshine" vitamin. J Pharmacol Pharmacother 2012;3:118–126.
27. Shaikh AS, Guo X, Li Y, et al. The impact of antiepileptic drugs on vitamin levels in epileptic patients. Curr Pharm Biotechnol 2018;19:674–681.
28. Teagarden DL, Meador KJ, Loring DW. Low vitamin D levels are common in patients with epilepsy. Epilepsy Res 2014;108:1352–1356.
29. Chaudhuri JR, Mridula KR, Rathnakishore C, et al. Association of 25-hydroxyvitamin D deficiency in pediatric epileptic patients. Iran J Child Neurol 2017;11:48–56.
30. Hadjipanayis A, Hadjichristodoulou C, Youroukos S. Epilepsy in patients with cerebral palsy. Dev Med Child Neurol 1997;39:659–663.
31. Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int. 2001;68:259–270.
32. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a metaanalysis. Osteoporos Int 2005;16:155–162.
33. Felson DT, Zhang Y, Hannan MT, et al. Alcohol intake and bone mineral density in elderly men and women. The Framingham Study. Am J Epidemiol 1995;142:485–492.
34. Sampson HW. Alcohol and other factors affecting osteoporosis risk in women. Alcohol Res Health 2002;26:292–298.
35. Russell RG. Bisphosphonates: the first 40 years. Bone 2011;49:2–19.
36. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54:1838–1846.
37. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077–2082.
38. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008;24:237–245.
39. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–1822.
40. Kaga Y, Ishii S, Kuroda I, et al. The efficacy of intravenous alendronate for osteoporosis in patients with severe motor intellectual disabilities. No To Hattatsu 2017;49:113–119 [in Japanese].
41. Hefti E. Factors affecting adherence in patients with intellectual disabilities. https://www.pharmacytimes.com/contributor/erik-hefti-pharmd-ms/2016/11/factors-affecting-adherence-in-patients-with-intellectual-disabilities
. Published November 7, 2016. Accessed February 7, 2021.
42. de Winter CF, Echteld MA, Evenhuis HM. Chronic kidney disease in older people with intellectual disability: results of the HA-ID study. Res Dev Disabil 2014;35:726–732.
43. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–1441.
44. Gilsenan A, Harding A, Kellier-Steele N, et al. The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporos Int 2018;29:2335–2343.
45. Lyu H, Jundi B, Xu C, et al. Comparison of denosumab and bisphosphonates in patients with osteoporosis: a meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2019;104:1753–1765.
46. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24:153–161.
47. Mok CC, Ho LY, Ma KM. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone 2015;75:222–228.
48. Martinkovich S, Shah D, Planey SL, et al. Selective estrogen receptor modulators: tissue specificity and clinical utility. Clin Interv Aging 2014;9:1437–1452.
49. Rey JRC, Cervino EV, Rentero ML, et al. Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. Open Orthop J 2009;3:14–21.
50. D'Amelio P, Isaia GC. The use of raloxifene in osteoporosis treatment. Expert Opin Pharmacother 2013;14:949–956.
51. Overman RA, Borse M, Gourlay ML. Salmon calcitonin use and associated cancer risk. Ann Pharmacother 2013;47:1675–1684.
52. Muñoz-Torres M, Alonso G, Mezquita Raya P. Calcitonin therapy in osteoporosis. Treat Endocrinol 2004;3:117–132.
53. Schousboe JT, Shepherd JA, Bilezikian JP, et al. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom 2013;16:455–466.
54. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2014;25:2359–2381.
55. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010;16(suppl 3):1–37.
56. Lewiecki EM, Watts NB. Assessing response to osteoporosis therapy. Osteoporos Int 2008;19:1363–1368.
57. Wheater G, Elshahaly M, Tuck SP, et al. The clinical utility of bone marker measurements in osteoporosis. J Transl Med 2013;11:201.
58. Eastell R, Vrijens B, Cahall DL, et al. Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J Bone Miner Res 2011;26:1662–1669.